Incentives and pharmaceutical reimbursement reforms in Spain

Health Policy

Volumn 67, Issue 2, 2004, Pages 149-165

  Puig Junoy, Jaume ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Negative list; Pharmaceutical industry; Pharmacy reimbursement; Reference pricing; Spanish health care system

Indexed keywords

CAPTOPRIL; FLUOXETINE; OMEPRAZOLE; RANITIDINE;

CONSUMER; DRUG COST; DRUG INDUSTRY; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; PHARMACY; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW; SPAIN;

EID: 0347948616     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(03)00113-1     Document Type: Article

References (18)

1. Costas A, Borrell JR. Competencia entre farmacias. El País 2000;(20 July):36.
2. Crespo B., Benedi A., Gómez V. Genéricos, financiación selectiva y nuevos principios activos: análisis de 1998. Revista de Administración Sanitaria. 12:1999;709-734.
3. Danzon P. Reference pricing: theory and evidence. In: López-Casasnovas G, Jonson B, editors. Reference pricing and pharmaceutical policy: perspectives on economics and innovation. Barcelona: Springer-Verlag; 2001. p. 86-126.
4. Ekelund M. Generic entry before and after the introduction of reference prices. In: Ekelund M, editor. Competition and innovation in the Swedish pharmaceutical market. Stockholm: Stockholm School of Economics; 2001.
5. European Observatory on Health Care Systems. Health systems in transition: Spain 2000. WHO Regional Office for Europe; 2000.
6. Evans D.B., Tandon A., Murray C.J.L., Lauer J.A. Comparative efficiency of national health systems: cross national econometric analysis. British Medical Journal. 323:2001;307-310.
7. Farmaindustria. The pharmaceutical industry in figures. Madrid: Farmaindustria; 2001.
8. Huskamp H.A., Rosenthal M.B., Frank R.G., Neuhouse J.P. The Medicare prescription drug benefit: how will the game be played? Health Affairs. 19(2):2000;8-23.
9. Ibern P. Copago farmacéutico: Nivel de concentración en pocos usuarios y diseño de alternativas. In: López-Casasnovas G, Callau J, editors. Libro de Ponencias de las XIX Jornadas de Economía de la Salud, Zaragoza, España, 2-4 June 1999. Huesca: Asociación de Economía de la Salud; 1999. p. 409-10.
10. López-Casasnovas G. Cost containment in health care: the case of the eighties to 1997. In: Mossialos E, Le Grand J, editors. Health care and cost containment in the European Union. Ashgate; 1999.
11. López-Casasnovas G., Puig-Junoy J. Review of the literature on reference pricing. Health Policy. 54:2000;87-123.
12. Martín N, Gutiérrez AM, Rodríguez AI. Los medicamentos excluidos de la financiación pública. Las decisiones de control del gasto de 1993 y 1998. Economía y Salud 2003;46:6-7.
13. Meneu R. Alternativas a la distribución de medicamentos y su retribución. Gac Sanit. 16(2):2001;171-181.
14. Nonell R., Borrell J.-R. Public demand for medicines, price regulation, and government-industry relationships in Spain. Environment and Planning C: Government and Policy. 19:2001;119-134.
15. Pavcnik N. Do pharmaceutical prices respond to insurance? Working Paper 7865. National Bureau of Economic Research; 2000.
16. Ribas J. Problemas relacionados con la medicación como causa del ingreso hospitalario. Medicina Clínica. 118:2002;6.
17. Rodríguez M., Scheffler R.M., Agnew J.D. An update on Spain's health care system: is it time for managed competition? Health Policy. 51:2000;109-131.
18. Rovira J, Darbà J. Pharmaceutical pricing and reimbursement in Spain. HEPAC 2001;39-43.